PATENT CLAIM ANALYSIS

Application Number: 16125317
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "133100"]

Abstract:
Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.

Claim (Index 51):
The method according to  claim 45 , wherein the disease or disorder is an inflammatory or immune disease or disorder selected from the group consisting of colitis, drug induced lupus nephritis, graft versus host disease, transplant rejection and atherosclerosis.

Metadata:
- Claim Count in Document: 92.0
- Percentile: 97.0
- Lexical Diversity: 1.05
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15667477', '12532517', '14309118', '11871136', '13656922']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7834294116738374
- 35 USC 102 Novelty (BERT): 0.6181938935360899
- Combined Prediction Score: 0.7669058598600627
- Mean Citation Score: 432.208416
- Max Citation Score: 687.2389
- Similarity Product: 472.6471482929229

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test